Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors
- 1 December 2002
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (12) , 1441-1445
- https://doi.org/10.1124/dmd.30.12.1441
Abstract
The effect of microsomal protein concentration on the inhibitory potency of a series of CYP3A inhibitors was assessed in vitro using diazepam 3-hydroxylation (yielding temazepam) as an index of CYP3A activity. With diazepam concentrations fixed at 100 μM, inhibition of temazepam formation by fixed concentrations of ritonavir, ketoconazole, itraconazole, OH-itraconazole, norfluoxetine, and fluvoxamine decreased substantially as active protein concentrations increased from 0.0625 to 3.0 mg/ml. However protein concentration had only a small effect on the inhibitory activity of fluconazole. Equilibrium dialysis indicated extensive microsomal binding of all inhibitors except fluconazole; binding increased with higher protein concentrations. Based on the CYP3A content of liver microsomes, decrements in inhibitory potency of stronger inhibitors (ketoconazole and ritonavir) could be explained by specific binding, whereas nonspecific binding is anticipated to account for the effect on weaker inhibitors (norfluoxetine and fluvoxamine). Thus, microsomal binding (specific, nonspecific, or a combination of both) may have a major effect on estimation of inhibitory potency of P450 inhibitors and may contribute to variations among laboratories. The effect can be minimized by use of the lowest possible microsomal protein concentration for in vitro studies of metabolic inhibition.Keywords
This publication has 14 references indexed in Scilit:
- Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro ModelsThe Journal of Clinical Pharmacology, 2001
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with RitonavirThe Journal of Clinical Pharmacology, 1998
- Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal AgentsThe Journal of Clinical Pharmacology, 1996
- Inhibition of Alprazolam and Desipramine Hydroxylation In Vitro by Paroxetine and FluvoxamineJournal of Clinical Psychopharmacology, 1995
- Diazepam metabolism by human liver microsomes is mediated by both S‐ mephenytoin hydroxylase and CYP3A isoforms.British Journal of Clinical Pharmacology, 1994
- Inhibitors of alprazolam metabolism in vitro: effect of serotonin- reuptake-inhibitor antidepressants, ketoconazole and quinidine.Published by Wiley ,1994
- Alprazolam Metabolism in vitro: Studies of Human, Monkey, Mouse, and Rat Liver MicrosomesPharmacology, 1993
- In vitro forecasting of drugs which may interfere with the biotransformation of midazolamEuropean Journal of Clinical Pharmacology, 1991
- Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolamJournal of Chromatography B: Biomedical Sciences and Applications, 1981